CLINICAL AND SUBCLINICAL CHARACTERISTICS IN PATIENTS WITH CHRONIC HEART FAILURE WITH TYPE 2 DIABETES AT KIEN GIANG GENERAL HOSPITAL IN 2021-2022
Main Article Content
Abstract
Background: Heart failure was one of the most common diseases and a serious complication experienced by 20-40% of patients with diabetes. Objectives: 1. Describe some clinical features in patients with heart failure with type 2 diabetes. 2. Describe some subclinical features in patients with heart failure with type 2 diabetes. Materials and methods: A cross-sectional descriptive study on 35 patients with heart failure and type 2 diabetes who came for examination and treatment at Kien Giang General Hospital from April 2021 to April 2022, and analyzed the data using SPSS 18.0 software. Results: Physical symptoms of fatigue appeared in of patients, exertional dyspnea was 78.6%; loss weight was 69.0%, lower costal pain was 61.9%, heart attack and acute pulmonary edema were 42.9%. Ankle edema is the most common physical symptom in 88.1% of patients, heart murmur was 66.7%, followed by left-sided heart, accounting for 59.5% and less common symptoms were jugular vein distension in 23.8%, cyanosis of the skin and mucous membranes was 21.4%. Patients with increased fasting glucose concentration (>7,2mmol/l) accounted for 88.1%; the patient's HbA1c index (≥7%) was 95.2%; Patients with ejection fraction 45% accounted for 38.1%. Conclusions: The most common symptoms were fatigue (92.9%), exertional dyspnea, chest pain, loss weight, lower costal tenderness; ankle edema is the most common physical symptom (88.1%); the patient's paraclinical indexes such as fasting glucose concentration, HbA1c index, NT-proBNP, ejection fraction all increased.
Article Details
Keywords
Heart failure, type 2 diabetes
References
2. Bộ Y tế (2020), Hướng dẫn chẩn đoán và điều trị đái tháo đường týp 2, Ban hành kèm theo Quyết định số 5481/QĐ-BYT ngày 30 tháng 12 năm 2020, Hà Nội.
3. Lương Công Thức (2018), Bệnh tim mạch ở người đái tháo đường, Trung tâm Tim mạch Bệnh viện Quân y 103.
4. Lam C (2019), Real world practices and outcomes in the management of heart failure patients with T2DM, Singapore.
5. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M (2019), Canagliflozin for Japanese patients with chronic heart failure and type II diabetes, Cardiovasc Diabetol, 18 (1).
6. Tousoulis D, Oikonomou E, Siasos G, Stefanadis C (2014), Diabetes Mellitus and Heart Failure., Eur Cardiol, 9 (1), pp. 37-42.
7. Wojcik C, Warden BA (2019), Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors, Curr Cardiol Rep, 21 (10).
8. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al (2019), SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, Lancet, 393 (10166), pp. 31-39.